|
Post by peppy on Jan 9, 2020 6:43:41 GMT -5
Aged is MDI. FYI.
And you beat me to it. Like I said, if we want to measure dicks by A1C...
That was pre Afrezza, that on a pump some 7 months ago. I don't have my hardcore GRIT days but that was with R and I got in the 4s. My next labs are Wednesday and Clarity is estimating 5.5. On Afrezza though... It's almost like it's not just the insulin or method of deliver you use that matters.
You are more than your A1C. You are more than your treatment decisions. You are more than your diabetes. You are more than your dietary decisions. You are more than your highs and lows.
Empathy goes a long way.
Just an update since I said I was getting labs and this is what would be possible with a different soc...
Tresiba + R + Afrezza
This was not expected at all. Dexcom estimated much higher.
HbA1c - 4.8. 91mg/dl www.screencast.com/t/ejbNh8seOkQ I remember learning 90 mg/dl was normal.
|
|
|
Post by agedhippie on Jan 9, 2020 9:34:31 GMT -5
In what way is a product being available and that product not being mainstream mutual contradictory? So yes I am saying that CGMs have been out for a long time, but they will not be mainstream for a long time. I got my Dexcom Seven Plus ten years ago (still have it somewhere!) so I think that qualifies as having been available for a long time. How are we doing for mainstream? In the US about 840,000 out of around 30 million diabetics have a CGM - that's less than 3%. My bet would be that this is almost entirely in the 10% of diabetics who are Type 1 which marries up to the idea that around 30% of Type 1s have a CGM. CGMs will go mainstream, but the insurers are going to delay that as long as humanly possible. The end-run would be to reduce the costs of CGMs to the point where insurance no longer matters, but that is not any time soon from what we can see over the next couple of years. Mike was hired because he knew how to market drugs. How is that going? "...If so why was the thread started?" Did you read the first post that I opened this thread with? If so you will see the thread was started to announce the arrival of the 2020 SoC. Why are some on this board saying the wording is new? Maybe for the same reason I wondered - they didn't put the , two versions side by side. Well I have done that now and they are identical barring the removal of some sub-headings. The reps are going to have the same wording as previously to work with. Aged - The words in the SoC are very powerful. Combined with the Affinity-1 analysis and the STAT Mike's reps can now give the endo's the reason to use afrezza with T1s; better control; less hypos. As you have said the reps could not market off-label until as I think most here now realize until study data was available which support these positions in the SoC. investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relativeMike has told us his 2020 target - T1 endos; and Mike now has no excuses for not executing. If Mike's reps can not sell the holy grail of diabetes care to endos now that they can tell the endos why they need to be using it, then I will join the threads asking for Mike's head. I am hoping 2020 is the beginning of something great for MNKD. I agree that the wording is useful. They are offset by what follows them. For those (sensibly) without the desire to plow through the SoC this is the relevant excerpt from page S109: "...inhaled insulin taken based on postprandial glucose levels may improve blood glucose management without additional hypoglycemia or weight gain, although results from a larger study are needed for confirmation." What they are saying that it may do these things, but that it requires a trial to confirm. That's the ADA giving those endos who are so inclined a pointer that is worth looking at, but it is stopping short of saying this is true, however this is not new. This is word for word what they said in the previous SoC. The change on the Mannkind side is that it looks like Mike has finally woken up to what the SoC is saying and realized that this is a lever that can be used with the endos - get the thought leaders and the others will follow. Meanwhile Mannkind needs to start planning that trial the ADA are suggesting if they want a better set of words.
|
|